Amrize (NYSE:AMRZ) Stock Gets Price Target Increase from UBS Group

Amrize (NYSE:AMRZ – Get Free Report) had its target price increased by investment analysts at UBS Group from $42.00 to $46.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group‘s price objective would suggest a potential upside of 14.08% from the stock’s current price.

Other analysts have also recently issued reports about the company. William Blair set a $40.00 price target on Amrize in a research note on Wednesday, September 2nd. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $60.00 price target on shares of Amrize in a report on Monday, September 21st. Berenberg Bank cut Amrize from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $48.00 to $46.00 in a research report on Monday, November 9th. Oppenheimer dropped their price objective on Amrize from $55.00 to $52.00 and set an “outperform” rating on the stock in a report on Monday, November 2nd. Finally, Truist Financial dropped their price objective on Amrize from $48.00 to $35.00 and set a “hold” rating on the stock in a report on Monday, October 5th. Eight research analysts have rated the stock with a Buy rating, seven have given a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, Amrize currently has a consensus rating of “Hold” and a consensus target price of $47.18.

Check Out Our Latest Stock Analysis on AMRZ

Amrize Stock Down 1.4%

NYSE:AMRZ traded down $0.57 during mid-day trading on Monday, hitting $40.32. The stock had a trading volume of 699,399 shares, compared to its average volume of 3,454,077. Amrize has a twelve month low of $35.78 and a twelve month high of $65.94. The stock has a 50-day simple moving average of $39.33 and a two-hundred day simple moving average of $49.98. The company has a current ratio of 1.07, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $22.30 billion, a PE ratio of 18.24, a PEG ratio of 1.60 and a beta of 0.03.

Amrize (NYSE:AMRZ – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.05 EPS for the quarter, meeting analysts’ consensus estimates of $1.05. The company had revenue of $3.77 billion for the quarter. Amrize had a net margin of 9.93% and a return on equity of 10.02%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 earnings per share. On average, equities research analysts anticipate that Amrize will post 2.30 EPS for the current year.

Insider Activity at Amrize

In related news, Director Jacques Sanche acquired 4,150 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were purchased at an average price of $45.02 per share, with a total value of $186,833.00. Following the completion of the acquisition, the director owned 9,766 shares in the company, valued at approximately $439,665.32. This represents a 73.90% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jan Jenisch bought 4,000 shares of the stock in a transaction on Wednesday, September 2nd. The stock was purchased at an average cost of $42.50 per share, for a total transaction of $170,000.00. Following the acquisition, the chief executive officer directly owned 519,000 shares of the company’s stock, valued at $22,057,500. The trade was a 0.78% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 34,155 shares of company stock valued at $1,461,276 in the last 90 days. Company insiders own 0.54% of the company’s stock.

Hedge Funds Weigh In On Amrize

Several institutional investors and hedge funds have recently modified their holdings of AMRZ. Pictet Asset Management Holding SA grew its holdings in shares of Amrize by 4.3% during the third quarter. Pictet Asset Management Holding SA now owns 6,126,150 shares of the company’s stock worth $230,110,000 after purchasing an additional 253,512 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its holdings in shares of Amrize by 8.8% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,102,975 shares of the company’s stock valued at $78,985,000 after buying an additional 170,551 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Amrize by 10.4% in the first quarter. Renaissance Technologies LLC now owns 1,956,600 shares of the company’s stock valued at $109,609,000 after buying an additional 183,900 shares during the last quarter. Amundi raised its holdings in shares of Amrize by 30.9% in the first quarter. Amundi now owns 1,654,739 shares of the company’s stock valued at $92,698,000 after buying an additional 390,750 shares during the last quarter. Finally, National Pension Service lifted its position in Amrize by 7.5% during the 2nd quarter. National Pension Service now owns 1,493,022 shares of the company’s stock worth $79,578,000 after buying an additional 103,962 shares in the last quarter.

About Amrize

(Get Free Report)

Amrize is a North American building materials and construction solutions company serving customers across the United States and Canada. Its operations span the construction materials and building envelope markets. The company supplies cement, aggregates, ready-mix concrete and asphalt, as well as roofing and other building-envelope products and services. These materials and solutions support residential, commercial and infrastructure projects. Amrize became an independent publicly traded company in 2025 through the spin-off of Holcim’s North American business.

Further Reading

Analyst Recommendations for Amrize (NYSE:AMRZ)

Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.